Angiographic quot;Blushquot; After Stereotactic Radiosurgery Ablation of Residual Arteriovenous Malformation in Pediatric Patient: Case Report and Review of Literature Journal Article

Local Library Link: Find It @ Loyola

Authors: Szujewski, C. C.; Heiferman, D. M.; Rosenbaum, M. D.; Reynolds, M. R.; Anderson, D. E.; Serrone, J. C.
Article Title: Angiographic quot;Blushquot; After Stereotactic Radiosurgery Ablation of Residual Arteriovenous Malformation in Pediatric Patient: Case Report and Review of Literature
Abstract: INTRODUCTION: While surgical resection remains a primary treatment for accessible arteriovenous malformations (AVMs), stereotactic radiosurgery (SRS) has become thoroughly integrated into the AVM armamentarium; however, delayed sequelae of this treatment have become evident with increased long-term follow-up. To our knowledge, this is the second case of an aberrant local arterial angiographic blush without early venous drainage or an associated lesion following AVM SRS. CASE DESCRIPTION: An 8-year-old female presented with a ruptured 4-cm right medial frontal periventricular Spetzler-Martin grade 3 AVM with isolated intraventricular hemorrhage. She underwent subtotal resection followed by SRS. Six years later, diagnostic cerebral angiography demonstrated a prominent arterial-phase filling microvasculature without early venous drainage in the region of the irradiated residual AVM nidus. CONCLUSION: Although there is a paucity of information on angiographic blush following AVM SRS, consensus in the literature suggests that without early venous drainage, these lesions appear to pose an insignificant threat to the patient. These angiographic findings may be on a spectrum of delayed cerebrovascular radiation changes, and thus indefinite follow-up may be considered, especially in pediatric patients.
Journal Title: World neurosurgery
Volume: 111
ISSN: 1878-8769; 1878-8750
Publisher: Unknown  
Journal Place: United States
Date Published: 2018
Start Page: 235
End Page: 239
Language: eng
DOI/URL:

S1878-8750(17)32225-8
Notes: LR: 20180303; CI: Published by Elsevier Inc.; JID: 101528275; OTO: NOTNLM; 2017/11/20 00:00 [received]; 2017/12/14 00:00 [revised]; 2017/12/15 00:00 [accepted]; 2017/12/31 06:00 [pubmed]; 2017/12/31 06:00 [medline]; 2017/12/31 06:00 [entrez]; ppublish